Amedisys, Inc. (NASDAQ: AMED), which was the subject of a recent acquisition by Janney Montgomery Scott LLC, was the target of the transaction, as stated in the most recent 13F filing that the company made with the Securities and Exchange Commission. The fund spent approximately $1,383,000 to purchase 14,290 shares of the company that provides healthcare services to acquire ownership of the business.
In the most recent few months, a variety of other hedge funds have modified the size of their positions in the company. During the third quarter, Leeward Investments LLC achieved a 60.5% increase in the proportion of Amedisys stock it owned. As a result of the purchase of an additional 54,339 shares during the most recent fiscal quarter, Leeward Investments LLC now holds a total of 144,091 shares of the stock held by the health services provider. The current price of these 144,091 shares puts their market value at $13,947,000. To increase its ownership stake in Amedisys and increase the amount of money it contributed to the company during the third quarter, the Louisiana State Employees Retirement System contributed approximately $832,000. During the third quarter, Pacer Advisors Inc. invested $185,000 in Amedisys by purchasing additional shares of the company’s stock. The National Bank of Canada Financial Institution increased its ownership of Amedisys by approximately 508,000 dollars during the third quarter of the fiscal year. And finally, during the second quarter, Federated Hermes Inc. increased its holdings in Amedisys by 9.4% by purchasing additional shares. Federated Hermes Inc. has increased the number of shares it owns in the health services provider by purchasing an additional 7,031 shares since the beginning of the most recent quarter. This brings the total number of shares it owns to 81,541, with a value of $8,572,000. The majority of the company’s shares, or 96.17%, are held in institutional investors’ portfolios.
During the most recent period, several research publications have centered on AMED as their primary topic of discussion. A research report by Barclays that was made public on Friday, October 28th, stated that the target price for Amedisys had decreased from $154.00 to $126,000.00. Barclays also assigned the company the rating of “overweight,” reflecting their bullish sentiment regarding the company. On Friday, November 4th, Cowen announced that they would be lowering their target price on Amedisys to $103.00. This news was included in a research note that was published that day. In a research note published on Friday, October 28th, Trust Financial lowered both the “buy” rating that they had previously assigned to Amedisys and the $140.00 price target that they had established for the stock to $130.00. Oppenheimer decreased their price objective on Amedisys from $175.00 to $145.00 in a research report published on Friday, October 28th.
Additionally, a “outperform” rating was bestowed upon the company’s stock by the company. In a research note published on Monday, October 24th, Deutsche Bank Aktiengesellschaft decreased both their “buy” rating and price target on Amedisys, which had previously been $175.00, to $165.00. This was the last and most important change. There have been ten different equity research analysts that have recommended buying the stock, fou.